ArticleDermatology and therapy2026
Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvaluating psoriasis care in Brazil, a country characterized by its vast geographical expanse, may provide valuable lessons for healthcare systems globally. National research has revealed that individuals receiving biologic treatments in Brazil exhibit lower drug survival rates than individuals from other countries, highlighting challenges that may be applicable elsewhere. The aim of this study was to determine whether distribution problems, poor adherence, and improper storage of immunobiological therapeutics are significant risk factors for reduced drug survival during psoriasis treatment.
methodsIn this retrospective cohort study, patients diagnosed with psoriasis who were receiving immunobiological therapy were enrolled in a real-world registry. Drug distribution, adherence, and storage problems were evaluated as risk factors. The primary endpoint was drug survival. Relative risk (RR) and Kaplan‒Meier analyses were used to assess associations, and multivariable analysis was performed via accelerated failure time modeling.
resultsAmong 166 patients, 82 (49.40%) discontinued treatment. Adalimumab was the most frequently administered biologic (n = 77), followed by secukinumab (n = 40), risankizumab (n = 9), guselkumab (n = 8), infliximab (n = 6), etanercept (n = 4), and ustekinumab (n = 19). Bimekizumab, brodalumab, and certolizumab pegol were each used by one patient. Distribution problems increased the risk of treatment interruption (RR = 1.45, 95% confidence interval [CI]: 1.07-1.95). After adjustment, the adverse impact of distribution problems diminished, most likely because of adalimumab's more frequent dosing schedule. Adalimumab use was linked to shorter drug survival (hazard ratio = 1.51, 95% CI: 1.01-2.27). Postinjection management also raised concerns: 22.23% of patients reported disposing of biologic waste in the regular trash.
conclusionsIn settings marked by significant stress within the distribution, storage, and administration chains for immunobiologics, distribution problems appear to negatively affect drug survival. The use of therapies with longer dosing intervals or oral medications may help overcome these barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.